The new Health Service Medical Supplies (Costs) Act 2017 came into force on 27 April 2017, giving the Department of Health greater powers to control the cost of medicines supplied to the National Health Service (NHS). The cost of branded medicines supplied to the NHS is regulated through two mechanisms – the Pharmaceutical Price Regulation
This week the Secretary of State for Health, Jeremy Hunt, announced that the Government will be investing £4.2 billion in digital health initiatives. The investment is part of the Government’s latest drive to create a “paperless” National Health Service (NHS) by 2020. The full details of the funding are still being agreed between the Department
On 6 November 2013, the Department of Health (“DoH”) and the Association of the British Pharmaceutical Industry (“ABPI”) announced Heads of Agreement for the new Pharmaceutical Price Regulation Scheme (the “2014 PPRS”). Entering into force on 1 January, the 2014 PPRS will replace the existing scheme (the “2009 PPRS”), which began in 2009 and is due to expire on 31 December of this this year.
The Confederation of British Industry (“CBI“) has revealed that it is developing “transparency guidelines” that will apply to private companies that provide services to the NHS (the “Guidelines“). The CBI’s public service strategy board, which includes managers and directors from some of the UK’s most high-profile outsourcing firms, will be responsible for drawing up the
In defiance of the First-tier Tribunal’s decision that the Department of Health should disclose a transition risk register advising on the risks of implementing the proposed reforms of the NHS, Andrew Lansley, the Health Secretary, has invoked a rarely-used ministerial veto and refused to publish the register. In doing so, Mr Lansley stated that while